leisure time -WSS

leisure time

author：comprehensive 2025-09-27 17:02:25 - browse：3

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Readout Newsletter: The latest on Amylyx, Moderna, Novavax

focus

WSS

Pfizer is about to make a big push in cancer. Will investors listen?

Doctor of U.S. President Joe Biden says he is fit for duty

Elisabeth Bik tackles the widespread issue of research misconduct

'Essentially witchcraft:' A former naturopath takes on the field

New report analyzes digital physical therapy solutions' effectiveness

Change Healthcare cyberattack shows risk of industry consolidation

hotspot

leisure time

leisure time

What does generative AI mean for health care? We asked experts

Study fuels hope CAR

Supreme Court strikes down use of affirmative action

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Affirmative action in medical school literally saved lives

5 takeaways from STAT's examination of Zynex Medical

Virginia high school admissions case could be legal follow

Teladoc has a new CEO, but challenges remain the same

Cancer drug shortages should be causing more outrage

STAT Virtual Event: ASCO Recap, Live!

leisure time

Report captures long Covid’s disabling effects and policy challenges

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Medical device trials still don't enroll enough women, study finds

Elisabeth Bik tackles the widespread issue of research misconduct

California wildfire smoke linked to 52,000 early deaths, study says

Teladoc has a new CEO, but challenges remain the same

focus

knowledge

knowledge

focus